In the BioHarmony Drug Report Database

"Preview" Icon

Alpelisib

Piqray (alpelisib) is a small molecule pharmaceutical. Alpelisib was first approved as Piqray on 2019-05-24. It is used to treat breast neoplasms and male breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. In addition, it is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. Piqray’s patents are valid until 2030-09-28 (FDA).

 

Trade Name

 

Piqray
 

Common Name

 

alpelisib
 

ChEMBL ID

 

CHEMBL2396661
 

Indication

 

breast neoplasms, male breast neoplasms
 

Drug Class

 

Phosphatidylinositol 3-kinase inhibitors

Image (chem structure or protein)

Alpelisib structure rendering